Good Shepherd Rehabilitation Network
850 S 5th St, Allentown, PA, 18103, United States
Overview
Founded in 1908 in Allentown, Pennsylvania, Good Shepherd Rehabilitation Network is a nationally recognized physical rehabilitation provider that offers an innovative continuum of care for adults and children with often complex physical and cognitive needs. Good Shepherd’s 2,100 Associates treat patients at more than 70 locations in Pennsylvania and New Jersey. Good Shepherd cares for adults and children with catastrophic injuries and conditions, such as spinal cord injury, brain injury, stroke, amputation and major multiple traumas and provides outpatient musculoskeletal and orthopedic rehabilitation services, home health, long-term acute care and long-term care. The Good Shepherd Physician Group is highly regarded for clinical excellence and its commitment to maximizing patients’ functional outcomes, delivering compassionate care and being a national leader in the use of innovative rehabilitation technologies. Good Shepherd physicians are experts who specialize in various aspects of rehabilitation care. Good Shepherd is the world’s leading clinical user of the Ekso Bionics® exoskeleton to treat patients with spinal cord injuries and was one of four facilities internationally designated by Ekso as a “Center for Robotic Excellence.” Good Shepherd’s long-term care facilities have consistently received 5-star ratings from US News and World Report.
- Total investments
- 1
- Lead investments
- 1
- Investments · 12mo
- 0
- Active investors
- 1
Sector focus
- Health Care
Investment portfolio
- Neuvotion
Led · Seed · Oct 2021
Neuvotion develops NeuStim™, a technology that combines highly targeted neurostimulation with artificial intelligence to accelerate rehabilitation and make physical and occupational therapy more effective. The company focuses on facilitating and restoring movement for patients impaired by stroke, traumatic injury, and other conditions. Neuvotion plans a multi-site clinical study to begin this year and intends to complete clinical studies using the new funding. Management says it will use the funds to expand its team and pursue FDA clearance for its initial product. Founded by Chad Bouton and based in Darien, CT, Neuvotion is in the early-stage clinical and regulatory phase. The company recently raised additional capital that brings its total funding to $2.75M. Neuvotion is an early-stage medical device company focused on facilitating and restoring movement for patients impaired by stroke, traumatic injury, and other conditions. Its core product, NeuStim™, combines highly targeted neurostimulation and artificial intelligence to make physical and occupational therapy more effective and efficient. The company is led by founder and CEO Chad Bouton and is based in Darien, CT. Neuvotion has received an exclusive worldwide license from Northwell Health for its technology. It raised over $1M in seed funding to advance development and clinical validation, and plans to use the proceeds to expand its team, conduct a multi-site clinical study next year, and pursue FDA clearance for its initial product.
Team
Michael Spigel
President and Chief Executive Officer
LinkedIn